Navigation Links
Genomic profiling of lung tumors helps doctors choose most effective treatment
Date:9/28/2007

DURHAM, N.C. -- Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.

A new study led by researchers from the Duke University Comprehensive Cancer Center and the Duke Institute for Genome Sciences & Policy (IGSP) found distinct differences in the susceptibility different tumors have to widely used chemotherapy drugs.

We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling, said David Hsu, M.D., Ph.D. an oncologist at Duke and lead author on the publication. This represents a big step in the move toward individualized medicine. This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy.

The researchers published their findings in the October 1, 2007 issue of the Journal of Clinical Oncology. The study was funded by the Jimmy V Foundation and the National Cancer Institute.

Researchers looked at the sensitivity of multiple cancerous cell lines to cisplatin, the most commonly used agent in the treatment of lung cancer. After determining which cell lines were responsive to cisplatin they looked at the RNA of these tumors and generated a genomic signature -- a pattern of gene expression particular to each individual sample. They were able to draw conclusions about which genes were turned on and which were turned off in these samples, and subsequently created a genomic map for cisplatin sensitivity. The genomic map was then applied to 91 non-small cell lung cancer (NSCLC) tumor samples to determine which tumors were most likely to be responsive to cisplatin, Hsu said.

We found that tumors known to be sensitive to cisplatin expressed certain
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Upcoming Hemogenomics Centre in Bangalore
2. Evoprinter, a multigenomic comparative tool for rapid identification of functionally important DNA
3. International Conference On Malaria - Laveran To Genomics
4. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
5. Nutrigenomics here comes a team to better your future!
6. Genomic tests for better cancer treatment
7. Web-Based Genomics Tool Designed to Help Predict Disease Susceptibility
8. AutoGenomics Addresses TB Crisis With a Genetic Drug Resistance Test
9. Pharmacogenomic Market Gaining Greater Acceptance Across Europe
10. Nutrient Profiling System Launched By Food Officials in UK
11. Proteomic Profiling Can Detect Preterm Birth Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...h Annual Physician On-Call Pay .../ -- Sullivan, Cotter and Associates, Inc.,has pub...ll pay rates and,practices, the 2008 Physician On-...ta from 132 healthcare organizations nationwide, o...paid for 33 physician specialty areas along,with d...
(Date:7/25/2008)...lusivity Begins -, CORONA, Calif., July 25 /PRNew...NYSE: WPI ), a leading specialty pharmaceutical,c...mmenced commercial,shipment of its Omeprazole Dela...gth from its Davie, Florida manufacturing facility...ays of marketing exclusivity for being the,first t...
(Date:7/25/2008)...ert J. Reilly, Joins Aethon Team, PITTSBURGH, Jul...on.com ), the leading developer of mobile robotics...ced that Robert J. Reilly has,joined the company a...., Reilly, who was most recently Vice President -...alty Pharmacy Division, brings more than 30,years ...
(Date:7/25/2008)...ekta Family of Companies will,showcase their uniqu...merican Association of Physicists in Medicine (AAP...ces of Elekta, IMPAC and CMS are delivering,cuttin...utions that,streamline the treatment process to cr...enhance clinician efficiency., "Our recent acquis...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...ther the reasons for swallowing the mobile phone b...or she purposely swallowed the mobile phone. // Th... in which it is said that the young lady purposely...th her boy friend in which she did not want to giv...
... two Israeli ophthalmologists Professor Michael Be...schleger Eye Institute at the Sheba Medical Centre...; They said that they have co-related all the prev...me out with strong evidences that obesity is the c...
...ave reported to have dead chicken and the cause th...ad chickens were tested and they showed positive r...placed an eastern town under scrutiny and have bee... of disease to other birds. The virus was first d...
...e polio eradication programme, initiated before 17...ent regions of the world. The programme was aimed ...of 2005. // The initiative, started in 1988, had a...adline has been set, and success may depend, in pa...
Other Medicine News:Health News:Increased Risk Of Losing Sight In Obese People. 2Health News:The Slow And Steady Race To Eradicate Polio Offers Hope 2
(Date:7/23/2008)...ing publication in July print edition of Clinical ... INDIANAPOLIS, July 23 /- A Roche Dia...of N-terminal pro-B-type natriuretic peptide,(NT-p...or risk,stratification in predicting the risk of c...reated with non-steroidal anti-inflammatory drugs ...
(Date:7/23/2008)...y 23 /- InCode BioPharmaceutics, Inc....ounced preclinical test,results demonstrating the ... treatment of the rare chronic blood disorder paro...e results will be presented at the XXII,Internatio...tember 28,2008., The only treatment currently av...
(Date:7/22/2008)...22 /- Nonin Medical, a leading innova... than 20 years, has entered,the clinical testing p...egional oxygen saturation. Today,s most common app...itoring of the regional blood oxygenation,in the b...d outcomes from an ongoing clinical study at the,D...
(Date:7/22/2008)...ing Lantus(R) and Apidra(R) Resulted in Significan...tes, Whatever the Algorithm ...wswire/ -- Results from the "Adjust to,Target in T...o Carbohydrate,Counting for Adjustment of Mealtime...merican Diabetes Association,s (ADA) medical journ...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 1TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 2TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 3TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 5TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 6TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 7Psychology com Seeing Growing Acceptance of Online Therapy 19145 1Psychology com Seeing Growing Acceptance of Online Therapy 19145 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 1Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 3Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 4Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 5Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 6Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 7NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 1NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 3
...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
...ETHESDA, Md., March 27, 2007--A new study shows th...e proportion of,cardiovascular disease (CVD) linke... emphasize the need for increased efforts to,preve...CVD risk,factors among those with diabetes, accord...amingham Heart Study, a program of the,National He...
Other Medicine Technology:Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter.
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company.
...dule is an inconspicuous, lightweight, battery-ope...need to hear body functions amplified., ,The modu... integrated on/off switch, a tone switch, a stetho... The tone switch will allow the user to select bet...
Medicine Products: